Sunitinib Malate

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 37, Issue , 2012, Pages 363-388

  Kassem, Mohammed Gabr ^a   Motiur Rahman, A F M ^a   Korashy, Hesham M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Analysis; Cytochrome P450; Sunitinib; Synthesis; Tyrosine kinase inhibitor

Indexed keywords

SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ABSORPTION SPECTROSCOPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FRAGMENTATION REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IMMUNOASSAY; KIDNEY CARCINOMA; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROFLUOROMETRY; SPECTROSCOPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY;

EID: 84858603542     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397220-0.00009-X     Document Type: Chapter

References (55)

1. Atkins M., Jones C.A., Kirkpatrick P. Sunitinib malate. Nat. Rev. Drug Discov. 2006, 5:279-280.
2. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
3. FDA Labeling information, 2009. http://www.fda.gov.
4. Rini B.I. Sunitinib. Expert Opin. Pharmacother. 2007, 8:2359-2369.
5. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., Booth B.P., Verbois S.L., Morse D.E., Liang C.Y., Chidambaram N., Jiang J.X., Tang S., Mahjoob K., Justice R., Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 2007, 13:1367-1373.
6. Sherman L., Peng G., Patyna S. Open-label, single-dose, phase I study evaluating the mass balance and pharmacokinetics (PKs) of sunitinib (SU) in healthy male subjects 2007.
7. Sweetman S. Sunitinib, Martindale: The Complete Drug Reference 2007, Pharmaceutical Press, London.
8. The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals 2006, Merck & Co., Inc., Whitehouse Station, NJ.
9. (for sunitinib), (for malate). http://en.wikipedia.org/wiki/Malic_acid.
10. Tang P., Miller T., Miller X., Sun L., Wei C., Shirazian S., Liang C., Vojkovsky T., Nematalla A., Hawley M. Chem. Abstr. 2001, 135:195497. Patent WO/192001/060814.
11. Moon M., Morozowich W., Gao P., Tang P.C. Chem. Abstr 2001, 136:697. Patent WO/2001/090068.
12. Etienne-Grimaldi M.C., Renee N., Izzedine H., Milano G. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:3757-3761.
13. Remko M., Boháč A., Kováčiková L. Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents. Struct. Chem. 2011, 22:635-648.
14. 2010 (accessed April 2010). http://www.acdlabs.com/products/phys_chem_lab/.
15. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34:D668-D672.
16. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2:471-478.
17. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007, 25:884-896.
18. Manley J.M., Kalman M.J., Conway B.G., Ball C.C., Havens J.L., Vaidyanathan R. Early amidation approach to 3-[(4-amido)pyrrol-2-yl]-2-indolinones. J. Org. Chem. 2003, 68:6447-6450.
19. Pettersson M. Sunitinib (Sutent): an angiogenesis inhibitor. Modern Drug Synthesis 2010, 87-98. John Wiley & Sons Inc., Malden, USA,. J.J. Li, D.S. Johnson (Eds.).
20. Wang J.Q., Miller K.D., Sledge G.W., Zheng Q.H. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg. Med. Chem. Lett. 2005, 15:4380-4384.
21. Elsinghorst P.W., Gutschow M. Synthesis of H-2- and C-13-labelled sunitinib and its primary metabolite. J. Labelled Comp. Rad. 2009, 52:360-365.
22. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.Y., Nematalla A., Wang X., Chen H., Sistla A., Luu T.C., Tang F., Wei J., Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46:1116-1119.
23. Treibs A., Hintermeier K. Chem. Ber. 1954, 86:1167.
24. Fisher H. Organic Synthesis 1943, 2. Wiley, New York, p. 202.
25. Beholz L.G., Benovsky P., Ward D.L., Barta N.S., Stille J.R. Formation of Dihydropyridone- and Pyridone-Based Peptide Analogs through Aza-Annulation of β-Enamino Ester and Amide Substrates with α-Amido Acrylate Derivatives. J. Org. Chem. 1997, 62(4):1033-1042.
26. Hafner K., Bernhard C. Angew. Chem. 1957, 69:533.
27. Manley J.M., Kalman M.J., Conway B.G., Ball C.C., Havens J.L., Vaidyanathan R. Early amidation approach to 3-[(4-amido)pyrrol-2-yl]-2-indolinones. J. Org. Chem 2003, 68:6447-6450.
28. Blanchet B., Saboureau C., Benichou A.S., Billemont B., Taieb F., Ropert S., Dauphin A., Goldwasser F., Tod M. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin. Chim. Acta 2009, 404:134-139.
29. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., Baker S.D. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 874:84-88.
30. Honeywell R., Yarzadah K., Giovannetti E., Losekoot N., Smit E.F., Walraven M., Lind J.S., Tibaldi C., Verheul H.M., Peters G.J. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2010, 878:1059-1068.
31. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:1982-1996.
32. Haznedar J.O., Patyna S., Bello C.L., Peng G.W., Speed W., Yu X., Zhang Q., Sukbuntherng J., Sweeny D.J., Antonian L., Wu E.Y. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother. Pharmacol. 2009, 64:691-706.
33. Zhou Q., Gallo J.M. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J. Pharm. Biomed. Anal. 2010, 51:958.
34. Lindauer A. Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Biomarker Response to Venlafaxine and Sunitinib Administration 2010.
35. Bouchet S., Chauzit E., Ducint D., Castaing N., Canal-Raffin M., Korashy Hesham M., Moore N., Titier K., Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin. Chim. Acta 2011, 412:1060-1067.
36. Li X.G., Wang G.F., Zhang J.Y., Wu S.Y., Xu W., Wu S.G., Zhang J.J. Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:1612-1614.
37. Ari{dotless}ci{dotless} M., Ki{dotless}li{dotless}nç M. Validated spectrofluorimetric method for the determination of sunitinib malate, dye complexation approach for a novel anticancer drug. Acta Pharm. Sci. 2010, 52:469-485.
38. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
39. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., Redman B.G., Margolin K.A., Merchan J.R., Wilding G., Ginsberg M.S., Bacik J., Kim S.T., Baum C.M., Michaelson M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
40. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
41. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M., Casali P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
42. Adams V.R., Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin. Ther. 2007, 29:1338-1353.
43. O'Brien S.G., Meinhardt P., Bond E., Beck J., Peng B., Dutreix C., Mehring G., Milosavljev S., Huber C., Capdeville R., Fischer T. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br. J. Cancer 2003, 89:1855-1859.
44. Tanaka C., Smith T., Kantarjian H. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL). J. Clin. Oncol. 2006, 24. 3095.
45. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 2007, 13:3731-3737.
46. Swaisland H.C., Ranson M., Smith R.P., Leadbetter J., Laight A., McKillop D., Wild M.J. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin. Pharmacokinet. 2005, 44:1067-1081.
47. Hazarika M., Jiang X., Liu Q., Lee S.L., Ramchandani R., Garnett C., Orr M.S., Sridhara R., Booth B., Leighton J.K., Timmer W., Harapanhalli R., Dagher R., Justice R., Pazdur R. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin. Cancer Res. 2008, 14:5325-5331.
48. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos. 2009, 37:359-365.
49. SUTENT (Sunitinib Malate) Prescribing Information 2009, Pfizer, Inc., New York (NY).
50. Mahmood S.T., Agresta S., Vigil C., Zhao X., Han G., D'Amato G., Calitri C.E., Dean M., Garrett C., Schell M.J., Antonia S., Chiappori A. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int. J. Cancer 2010.
51. Sakamoto K.M. Su-11248 Sugen. Curr. Opin. Investig. Drugs 2004, 5:1329-1339.
52. Bello C.L., Sherman L., Zhou J., Verkh L., Smeraglia J., Mount J., Klamerus K.J. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006, 17:353-358.
53. Bello C.L., Garrett M., Sherman L., Smeraglia J., Ryan B., Toh M. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother. Pharmacol. 2010, 66:699-707.
54. Desar I.M., Burger D.M., Van Hoesel Q.G., Beijnen J.H., Van Herpen C.M., Van der Graaf W.T. Pharmacokinetics of sunitinib in an obese patient with a GIST. Ann. Oncol. 2009, 20:599-600.
55. Izzedine H., Etienne-Grimaldi M.C., Renee N., Vignot S., Milano G. Pharmacokinetics of sunitinib in hemodialysis. Ann. Oncol. 2009, 20:190-192.